Circumspective | Published:

Food addiction: a valid concept?

Neuropsychopharmacologyvolume 43pages25062513 (2018) | Download Citation

  • A Correction to this article was published on 07 December 2018

Abstract

Can food be addictive? What does it mean to be a food addict? Do common underlying neurobiological mechanisms contribute to drug and food addiction? These vexing questions have been the subject of considerable interest and debate in recent years, driven in large part by the major health concerns associated with dramatically increasing body weights and rates of obesity in the United States, Europe, and other regions with developed economies. No clear consensus has yet emerged on the validity of the concept of food addiction and whether some individuals who struggle to control their food intake can be considered food addicts. Some, including Fletcher, have argued that the concept of food addiction is unsupported, as many of the defining features of drug addiction are not seen in the context of feeding behaviors. Others, Kenny included, have argued that food and drug addiction share similar features that may reflect common underlying neural mechanisms. Here, Fletcher and Kenny argue the merits of these opposing positions on the concept of food addiction.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Jaspers K. General psychopathology. Manchester: Manchester University Press; 1963.

  2. 2.

    Davis C. Evolutionary and neuropsychological perspectives on addictive behaviors and addictive substances: relevance to the “food addiction” construct. Subst Abus Rehabil. 2014;5:129–37.

  3. 3.

    Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite. 2009;52:430–6.

  4. 4.

    Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013;14:2–18.

  5. 5.

    Pedram P, Wadden D, Amini P, Gulliver W, Randell E, Cahill F, et al. Food addiction: its prevalence and significant association with obesity in the general population. PLoS ONE. 2013;8:e74832.

  6. 6.

    Hebebrand J, Albayrak O, Adan R, Antel J, Dieguez C, de Jong J, et al. “Eating addiction”, rather than “food addiction”, better captures addictive-like eating behavior. Neurosci Biobehav Rev. 2014;47:295–306.

  7. 7.

    Schulte EM, Potenza MN, Gearhardt AN. A commentary on the “eating addiction” versus “food addiction” perspectives on addictive-like food consumption. Appetite. 2017;115:9–15.

  8. 8.

    Westwater ML, Fletcher PC, Ziauddeen H. Sugar addiction: the state of the science. Eur J Nutr. 2016;55(Suppl 2):55–69.

  9. 9.

    de Vries SK, Meule A. Food addiction and bulimia nervosa: new data based on the Yale Food Addiction Scale 2.0. Eur Eat Disord Rev. 2016;24:518–22.

  10. 10.

    Hilker I, Sanchez I, Steward T, Jimenez-Murcia S, Granero R, Gearhardt AN, et al. Food addiction in bulimia nervosa: clinical correlates and association with response to a brief psychoeducational intervention. Eur Eat Disord Rev. 2016;24:482–8.

  11. 11.

    Meule A, Heckel D, Kubler A. Factor structure and item analysis of the Yale Food Addiction Scale in obese candidates for bariatric surgery. Eur Eat Disord Rev. 2012;20:419–22.

  12. 12.

    Meule A, von Rezori V, Blechert J. Food addiction and bulimia nervosa. Eur Eat Disord Rev. 2014;22:331–7.

  13. 13.

    Gearhardt AN, White MA, Masheb RM, Morgan PT, Crosby RD, Grilo CM. An examination of the food addiction construct in obese patients with binge eating disorder. Int J Eat Disord. 2012;45:657–63.

  14. 14.

    Finlayson G. Food addiction and obesity: unnecessary medicalization of hedonic overeating. Nat Rev Endocrinol. 2017;13:493–8.

  15. 15.

    Long CG, Blundell JE, Finlayson G. A systematic review of the application and correlates of YFAS-diagnosed ‘food addiction’ in humans: are eating-related ‘addictions’ a cause for concern or empty concepts? Obes Facts. 2015;8:386–401.

  16. 16.

    Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet. 2001;357:354–7.

  17. 17.

    Dang LC, Samanez-Larkin GR, Castrellon JJ, Perkins SF, Cowan RL, Zald DH. Associations between dopamine D2 receptor availability and BMI depend on age. Neuroimage. 2016;138:176–83.

  18. 18.

    Eisenstein SA, Bischoff AN, Gredysa DM, Antenor-Dorsey JA, Koller JM, Al-Lozi A, et al. Emotional eating phenotype is associated with central dopamine D2 receptor binding independent of body mass index. Sci Rep. 2015;5:11283.

  19. 19.

    Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, et al. Obesity is associated with decreased mu-opioid but unaltered dopamine D2 receptor availability in the brain. J Neurosci. 2015;35:3959–65.

  20. 20.

    Ziauddeen H, Farooqi IS, Fletcher PC. Obesity and the brain: how convincing is the addiction model? Nat Rev Neurosci. 2012;13:279–86.

  21. 21.

    Ziauddeen H, Fletcher PC. Is food addiction a valid and useful concept? Obes Rev. 2013;14:19–28.

  22. 22.

    Corwin RL. The face of uncertainty eats. Curr Drug Abus Rev. 2011;4:174–81.

  23. 23.

    Furlong TM, Jayaweera HK, Balleine BW, Corbit LH. Binge-like consumption of a palatable food accelerates habitual control of behavior and is dependent on activation of the dorsolateral striatum. J Neurosci. 2014;34:5012–22.

  24. 24.

    Avena NM, Gearhardt AN, Gold MS, Wang GJ, Potenza MN. Tossing the baby out with the bathwater after a brief rinse? The potential downside of dismissing food addiction based on limited data. Nat Rev Neurosci. 2012;13:514. author reply 514

  25. 25.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington, VA: American Psychiatric Publishing; 2013.

  26. 26.

    Puhl RM, Moss-Racusin CA, Schwartz MB, Brownell KD. Weight stigmatization and bias reduction: perspectives of overweight and obese adults. Health Educ Res. 2008;23:347–58.

  27. 27.

    Booth ML, Wilkenfeld RL, Pagnini DL, Booth SL, King LA. Perceptions of adolescents on overweight and obesity: the weight of opinion study. J Paediatr Child Health. 2008;44:248–52.

  28. 28.

    Saunders R. Compulsive eating and gastric bypass surgery: what does hunger have to do with it? Obes Surg. 2001;11:757–61.

  29. 29.

    Small DM, Zatorre RJ, Dagher A, Evans AC, Jones-Gotman M. Changes in brain activity related to eating chocolate: from pleasure to aversion. Brain. 2001;124(Pt 9):1720–33.

  30. 30.

    Stice E, Yokum S, Burger KS, Epstein LH, Small DM. Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci. 2011;31:4360–6.

  31. 31.

    Yokum S, Gearhardt AN, Harris JL, Brownell KD, Stice E. Individual differences in striatum activity to food commercials predict weight gain in adolescents. Obesity (Silver Spring). 2014;22:2544–51.

  32. 32.

    Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008;322:449–52.

  33. 33.

    Stice E, Yokum S. Gain in body fat is associated with increased striatal response to palatable food cues, whereas body fat stability is associated with decreased striatal response. J Neurosci. 2016;36:6949–56.

  34. 34.

    Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 2010;30:13105–9.

  35. 35.

    van der Klaauw AA, von dem Hagen EA, Keogh JM, Henning E, O’Rahilly S, Lawrence AD, et al. Obesity-associated melanocortin-4 receptor mutations are associated with changes in the brain response to food cues. J Clin Endocrinol Metab. 2014;99:E2101–6.

  36. 36.

    Holsen LM, Zarcone JR, Thompson TI, Brooks WM, Anderson MF, Ahluwalia JS, et al. Neural mechanisms underlying food motivation in children and adolescents. Neuroimage. 2005;27:669–76.

  37. 37.

    Killgore WD, Weber M, Schwab ZJ, Kipman M, DelDonno SR, Webb CA, et al. Cortico-limbic responsiveness to high-calorie food images predicts weight status among women. Int J Obes (Lond). 2013;37:1435–42.

  38. 38.

    Killgore WD, Young AD, Femia LA, Bogorodzki P, Rogowska J, Yurgelun-Todd DA. Cortical and limbic activation during viewing of high- versus low-calorie foods. Neuroimage. 2003;19:1381–94.

  39. 39.

    Scholtz S, Miras AD, Chhina N, Prechtl CG, Sleeth ML, Daud NM, et al. Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut. 2014;63:891–902.

  40. 40.

    Siep N, Roefs A, Roebroeck A, Havermans R, Bonte ML, Jansen A. Hunger is the best spice: an fMRI study of the effects of attention, hunger and calorie content on food reward processing in the amygdala and orbitofrontal cortex. Behav Brain Res. 2009;198:149–58.

  41. 41.

    van Bloemendaal L, RGI J, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186–96.

  42. 42.

    Geiger BM, Haburcak M, Avena NM, Moyer MC, Hoebel BG, Pothos EN. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience. 2009;159:1193–9.

  43. 43.

    Martel P, Fantino M. Influence of the amount of food ingested on mesolimbic dopaminergic system activity: a microdialysis study. Pharmacol Biochem Behav. 1996;55:297–302.

  44. 44.

    Bassareo V, Di Chiara G. Modulation of feeding-induced activation of mesolimbic dopamine transmission by appetitive stimuli and its relation to motivational state. Eur J Neurosci. 1999;11:4389–97.

  45. 45.

    Blackburn JR, Phillips AG, Jakubovic A, Fibiger HC. Increased dopamine metabolism in the nucleus accumbens and striatum following consumption of a nutritive meal but not a palatable non-nutritive saccharin solution. Pharmacol Biochem Behav. 1986;25:1095–100.

  46. 46.

    Wilson C, Nomikos GG, Collu M, Fibiger HC. Dopaminergic correlates of motivated behavior: importance of drive. J Neurosci. 1995;15(7 Pt 2):5169–78.

  47. 47.

    Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev: 2007;CD005353.

  48. 48.

    Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M. Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial. Nicotine Tob Res. 2017;19:944–51.

  49. 49.

    Ahmed SH, Guillem K, Vandaele Y. Sugar addiction: pushing the drug-sugar analogy to the limit. Curr Opin Clin Nutr Metab Care. 2013;16:434–9.

  50. 50.

    Colantuoni C, Rada P, McCarthy J, Patten C, Avena NM, Chadeayne A, et al. Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence. Obes Res. 2002;10:478–88.

  51. 51.

    DiFeliceantonio AG, Coppin G, Rigoux L, Thanarajah SE, Dagher A, Tittgemeyer M, et al. Supra-additive effects of combining fat and carbohydrate on food reward. Cell Metab. 2018;28:33–44.e3.

  52. 52.

    Decorte T. Quality control by cocaine users: underdeveloped harm reduction strategies. Eur Addict Res. 2001;7:161–75.

  53. 53.

    National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Patterns of tobacco use among U.S. youth, young adults, and adults. In: (US)CfDCaP, editor. The health consequences of smoking-50 years of progress: a report of the surgeon general. US Department of Health and Human Services, Atlanta, GA; 2014.

  54. 54.

    Russell MA. The smoking habit and its classification. Practitioner. 1974;212:791–800.

  55. 55.

    Warburton DM. Is nicotine use an addiction? Psychologist. 1989;4:166–70.

  56. 56.

    Gawin FH. Cocaine addiction: psychology and neurophysiology. Science. 1991;251:1580–6.

  57. 57.

    Teufel C, Fletcher PC. The promises and pitfalls of applying computational models to neurological and psychiatric disorders. Brain. 2016;139(Pt 10):2600–8.

  58. 58.

    Russo SJ, Dietz DM, Dumitriu D, Morrison JH, Malenka RC, Nestler EJ. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 2010;33:267–76.

  59. 59.

    Kalivas PW. Glutamate systems in cocaine addiction. Curr Opin Pharmacol. 2004;4:23–9.

  60. 60.

    Scofield MD, Heinsbroek JA, Gipson CD, Kupchik YM, Spencer S, Smith AC, et al. The nucleus accumbens: mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis. Pharmacol Rev. 2016;68:816–71.

  61. 61.

    O’Rahilly S, Farooqi IS. Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes. 2008;57:2905–10.

  62. 62.

    Kenny PJ, Hoyer D, Koob GF. Animal models of addiction and neuropsychiatric disorders and their role in drug discovery: honoring the legacy of Athina Markou. Biol Psychiatry. 2018;83:940–6.

  63. 63.

    Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59:29–53.

  64. 64.

    Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl). 2010;210:121–35.

  65. 65.

    Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13:635–41.

  66. 66.

    Ersche KD, Gillan CM, Jones PS, Williams GB, Ward LH, Luijten M, et al. Carrots and sticks fail to change behavior in cocaine addiction. Science. 2016;352:1468–71.

  67. 67.

    Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8:1481–9.

  68. 68.

    Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science. 2004;305:1014–7.

  69. 69.

    Vanderschuren LJ, Everitt BJ. Drug seeking becomes compulsive after prolonged cocaine self-administration. Science. 2004;305:1017–9.

  70. 70.

    Tantot F, Parkes SL, Marchand AR, Boitard C, Naneix F, Laye S, et al. The effect of high-fat diet consumption on appetitive instrumental behavior in rats. Appetite. 2017;108:203–11.

  71. 71.

    Chen BT, Yau HJ, Hatch C, Kusumoto-Yoshida I, Cho SL, Hopf FW, et al. Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. Nature. 2013;496:359–62.

  72. 72.

    Diana M, Raij T, Melis M, Nummenmaa A, Leggio L, Bonci A. Rehabilitating the addicted brain with transcranial magnetic stimulation. Nat Rev Neurosci. 2017;18:685–93.

  73. 73.

    Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Gallimberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: a pilot study. Eur Neuropsychopharmacol. 2016;26:37–44.

  74. 74.

    Thompson JL, Drysdale M, Baimel C, Kaur M, MacGowan T, Pitman KA, et al. Obesity-induced structural and neuronal plasticity in the lateral orbitofrontal cortex. Neuropsychopharmacology. 2017;42:1480–90.

  75. 75.

    Medic N, Ziauddeen H, Ersche KD, Farooqi IS, Bullmore ET, Nathan PJ, et al. Increased body mass index is associated with specific regional alterations in brain structure. Int J Obes (Lond). 2016;40:1177–82.

  76. 76.

    Freese L, Durand A, Guillem K, Ahmed SH. Pre-trial cocaine biases choice toward cocaine through suppression of the nondrug option. Pharmacol Biochem Behav. 2018;173:65–73.

  77. 77.

    Huynh C, Fam J, Ahmed SH, Clemens KJ. Rats quit nicotine for a sweet reward following an extensive history of nicotine use. Addict Biol. 2017;22:142–51.

  78. 78.

    Lenoir M, Cantin L, Vanhille N, Serre F, Ahmed SH. Extended heroin access increases heroin choices over a potent nondrug alternative. Neuropsychopharmacology. 2013;38:1209–20.

  79. 79.

    Madsen HB, Ahmed SH. Drug versus sweet reward: greater attraction to and preference for sweet versus drug cues. Addict Biol. 2015;20:433–44.

  80. 80.

    Cantin L, Lenoir M, Augier E, Vanhille N, Dubreucq S, Serre F, et al. Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction. PLoS ONE. 2010;5:e11592.

  81. 81.

    Augier E, Barbier E, Dulman RS, Licheri V, Augier G, Domi E, et al. A molecular mechanism for choosing alcohol over an alternative reward. Science. 2018;360:1321–6.

  82. 82.

    Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.

  83. 83.

    Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197–206.

  84. 84.

    Munafo MR, Matheson IJ, Flint J. Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Mol Psychiatry. 2007;12:454–61.

  85. 85.

    Sanchez-Roige S, Gray JC, MacKillop J, Chen CH, Palmer AA. The genetics of human personality. Genes Brain Behav. 2018;17:e12439.

  86. 86.

    Farooqi IS, Bullmore E, Keogh J, Gillard J, O’Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317:1355.

  87. 87.

    Owens AP, Allen M, Ondobaka S, Friston KJ. Interoceptive inference: from computational neuroscience to clinic. Neurosci Biobehav Rev. 2018;90:174–83.

  88. 88.

    Tallon-Baudry C, Campana F, Park HD, Babo-Rebelo M. The neural monitoring of visceral inputs, rather than attention, accounts for first-person perspective in conscious vision. Cortex. 2018;102:139–49.

  89. 89.

    Morris LS, Voon V, Leggio L. Stress, motivation, and the gut-brain axis: a focus on the ghrelin system and alcohol use disorder. Alcohol Clin Exp Res. 2018.

  90. 90.

    Wilson GT. Eating disorders, obesity and addiction. Eur Eat Disord Rev. 2010;18:341–51.

Download references

Acknowledgements

PCF is supported by the Wellcome Trust and the Bernard Wolfe Health Neuroscience Fund. He is grateful to Hisham Ziauddeen and Margaret Westwater for their erudite discussion and suggestions around this topic. PJK was supported by the National Institutes of Health and is grateful to Drs. Alexandra DiFeliceantonio and Richard O’Connor for helpful discussions.

Author information

Affiliations

  1. Department of Psychiatry, University of Cambridge, Cambridge, CB2 8AH, UK

    • Paul C. Fletcher
  2. Cambridgeshire and Peterborough NHS Foundation Trust, Cambrdge, CB21 5EF, UK

    • Paul C. Fletcher
  3. Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    • Paul J. Kenny

Authors

  1. Search for Paul C. Fletcher in:

  2. Search for Paul J. Kenny in:

Competing interests

PJK is a co-founder and shareholder in Eolas Therapeutics Inc., has a patent license agreement with AstraZeneca, receives research support from Eli Lilly, and has received consulting fees from Takenda Pharmaceuticals, USA. PCF has received consulting fees from GlaxoSmithKline.

Corresponding author

Correspondence to Paul C. Fletcher.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41386-018-0203-9